Upstream Bio, Inc.

NASDAQ:UPB

Biotechnology

Healthcare
$2.08 +1.63%

+$0.10 today

Market cap
$114.01M
Beta
1.11
P/E (TTM)
-2.2
EPS (TTM)
-$2.89
52W Low $5.85High $33.68

Volume 1.24M

Average 0.66M

UPB Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Upstream Bio, Inc.NASDAQ: UPB

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue growth accelerates

Q1 FY2026 revenue of $1.03M rose 82.7% year over year, ahead of the +44.7% change in trailing-twelve-month revenue. Sequentially, it rose 54.8% from the prior quarter. Over 3 fiscal years it compounded at +33.0% a year.

Context

  • Revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 5 analysts of $2.59M (-9.1%) for the fiscal year ending Dec 2026, a slowdown from the +20.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.03M+54.8% QoQ
Last fiscal yearDec 2025
$2.85M+20.4% YoY
LTMMar 2026
$3.32M+44.7% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+82.7%-54.0%-136.7 pp
1 year+20.4%-9.1%-29.5 pp
3-year CAGR+33.0%+9.9%-23.1 pp
5-year CAGR+76.3%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
2.85M USD
Year-over-year change
+20.4%
3-year CAGR
+33.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How UPB compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +44.7% is the 4th highest of 8, against a peer median of +23.9%.
  • Over three fiscal years its annual growth of +33.0% compares with a peer median of +66.1%.
UPB Competitors
Revenue for UPB and competitors
Company Period LTM YoY 3-year CAGR
NVAXNovavax, Inc.LTM Mar 2026$596.34M USD-52.5%-11.1%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$217.17M USD+396.7%—
SYRESpyre Therapeutics, Inc.LTM Sep 2026$90.49M USD——
WVEWave Life Sciences Ltd.LTM Mar 2026$71.8M USD-31.6%+127.1%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$66.09M USD+45.0%+9.1%
RLAYRelay Therapeutics, Inc.LTM Jun 2026$10.35M USD+23.9%+123.2%
UPBUpstream Bio, Inc.LTM Mar 2026$3.32M USD+44.7%+33.0%
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$0 USD+100.0%—
PHVSPharvaris N.V.LTM Sep 2026€0 EUR——
ZBIOZenas BioPharma, Inc.LTM Mar 2026$0 USD-100.0%—
Peer median (excluding UPB) —+23.9%+66.1%

Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.21M2.38M2.37M2.85M
Cost of Revenue0000
Gross Profit1.21M2.38M2.37M2.85M
Gross Margin100.0%100.0%100.0%100.0%
Research & Development18.66M31.8M62.97M136.81M
Selling, General & Admin6.46M10.7M17.17M26.41M
Operating Expenses25.12M42.49M80.13M163.22M
Depreciation & Amortization7K60K89K188K
EBITDA(23.86M)(20.48M)(62.72M)(143.26M)
EBITDA Margin-1968.7%-860.4%-2646.3%-5019.4%
Operating Income(23.91M)(40.11M)(77.76M)(160.36M)
Operating Margin-1972.7%-1685.5%-3281.2%-5618.8%
Interest Income205K4.17M12.12M16.93M
Interest Expense0000
Other Income / Expenses41K19.58M14.96M16.92M
Income Before Tax(23.87M)(20.54M)(62.81M)(143.44M)
Pre-Tax Margin-1969.3%-862.9%-2650.0%-5026.0%
Income Tax Expense0000
Net Income(23.87M)(20.54M)(62.81M)(143.44M)
Net Margin-1969.3%-862.9%-2650.0%-5026.0%
EPS (Basic)(0.66)(1.05)(1.49)(2.66)
EPS (Diluted)(0.66)(1.05)(1.49)(2.66)
Weighted Avg Shares36.32M36.32M51.34M53.85M
Weighted Avg Shares (Diluted)36.32M36.32M51.34M53.85M

Upstream Bio, Inc.

NASDAQ:UPB

Intrinsic Alpha fair value

Locked

Current Price

$2.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.